Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate

被引：28
|
作者：
Rousselot, P [1 ]
Larghero, J
Raffoux, E
Calvo, F
Tulliez, M
Giraudier, S
Rybojad, M
机构：
[1] Hop St Louis, Serv Clin Malad Sang, Paris, France
[2] Hop St Louis, Ctr Invest Clin, Paris, France
[3] Hop Henri Mondor, Hematol Lab, F-94010 Creteil, France
[4] Hop St Louis, Serv Dermatol, F-75475 Paris, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2003年 / 120卷 / 06期
关键词：
imatinib mesylate; c-Kit; chronic myelogenous leukaemia; photosensitivity; depigmentation;
D O I：
10.1046/j.1365-2141.2003.04208_3.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1091 / 1092
页数：2
相关论文
共 50 条
  • [41] The role of α-interferon in chronic myelogenous leukaemia in imatinib era
    Franceschini, R
    Zoppi, F
    Garuti, A
    Gobbi, M
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2004, 23 (04): : 697 - 698
  • [42] Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
    Bueso-Ramos, CE
    Cortes, J
    Talpaz, M
    O'Brien, S
    Giles, F
    Rios, MB
    Medeiros, LJ
    Kantarjian, H
    CANCER, 2004, 101 (02) : 332 - 336
  • [43] Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?
    Keisuke Miyazawa
    Jiroh Nishimaki
    Tomoko Katagiri
    Goro Sashida
    Nahoko Shoji
    Ken Kawakubo
    Akitaka Suzuki
    Takashi Shimamoto
    Akihiko Gotoh
    Yuzuru Kuriyama
    Yoshikazu Ito
    Tetsuzo Tauchi
    Yoshikazu Kawanishi
    Yukihiko Kimura
    Kazuma Ohyashiki
    International Journal of Hematology, 2003, 77 : 93 - 95
  • [44] Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: Is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?
    Miyazawa, K
    Nishimaki, J
    Katagiri, T
    Sashida, G
    Shoji, N
    Kawakubo, K
    Suzuki, A
    Shimamoto, T
    Gotoh, A
    Kuriyama, Y
    Ito, Y
    Tauchi, T
    Kawanishi, Y
    Kimura, Y
    Ohyashiki, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (01) : 93 - 95
  • [45] Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
    Cervantes, F
    Hernández-Boluda, JC
    Odriozola, J
    Camós, M
    Villalón, L
    Martínez-Climent, JA
    Del Campo, R
    García-Conde, J
    Montserrat, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) : 500 - 504
  • [46] AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF IMATINIB REISTANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA
    Taylor, M.
    Lewis, L.
    Lebmeier, M.
    Wang, Q.
    VALUE IN HEALTH, 2011, 14 (03) : A166 - A167
  • [47] Five-year Follow-up of Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukaemia in Trinidad and Tobago
    Charles, K. S.
    Ramon, L.
    Leelah, N.
    Oluwabusi, T. A. A.
    Seemungal, T.
    WEST INDIAN MEDICAL JOURNAL, 2011, 60 (03): : 298 - 302
  • [48] Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate
    Lau, Y. M.
    Lam, Y. K.
    Leung, K. H.
    Lin, S. Y.
    HONG KONG MEDICAL JOURNAL, 2014, 20 (05)
  • [49] Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
    Arora, B
    Kumar, L
    Sharma, A
    Wadhwa, J
    Kochupillai, V
    ANNALS OF ONCOLOGY, 2004, 15 (02) : 358 - 359
  • [50] Cytogenetic responses in chronic myeloid leukemia patients treated with imatinib mesylate
    Babameto-Laku, A.
    Mokin, V.
    Cikuli, M.
    Xhumari, P.
    CHROMOSOME RESEARCH, 2005, 13 : 158 - 158
12345